This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cleare, A. J. Search for Related Content PubMed PubMed Citation Articles by Cleare, A. J.

The Neuroendocrinology of Chronic Fatigue Syndrome

Section of Neurobiology of Mood Disorders, Division of Psychological Medicine, The Institute of Psychiatry, London SE5 8AZ, United Kingdom

Correspondence: Address all correspondence and requests for reprints to: A. J. Cleare, Section of Neurobiology of Mood Disorders, Division of Psychological Medicine, The Institute of Psychiatry, 103 Denmark Hill, London SE5 8AZ, United Kingdom. E-mail: a.cleare{at}iop.kcl.ac.uk.

Chronic fatigue syndrome (CFS) is a common and disabling problem; although most likely of biopsychosocial origin, the nature of the pathophysiological components remains unclear. There has been a wealth of interest in the endocrinology of this condition, which will be reviewed in this article. Most studied has been the hypothalamic-pituitary-adrenal (HPA) axis; although the quality of many studies is poor, the overall balance of evidence points to reduced cortisol output in at least some patients, with some evidence that this is linked to symptom production or persistence. There is evidence for heightened negative feedback and glucocorticoid receptor function and for impaired ACTH and cortisol responses to a variety of challenges. However, there is no evidence for a specific or uniform dysfunction of the HPA axis. Given the many factors that may impinge on the HPA axis in CFS, such as inactivity, sleep disturbance, psychiatric comorbidity, medication, and ongoing stress, it seems likely that HPA axis disturbance is heterogeneous and of multifactorial etiology in CFS. Studies assessing GH, dehydroepiandrostenedione and its sulfate, melatonin, leptin, and neuroendocrine-monoamine interactions are also reviewed. There is some evidence from these studies to suggest alterations of dehydroepiandrostenedione sulfate function and abnormal serotonin function in CFS, but whether these changes are of functional importance remains unclear. To obtain a clearer assessment of the etiological and pathophysiological relevance of endocrine changes in CFS, it is suggested that more prospective cohort studies be undertaken in groups at high risk for CFS, that patients with CFS are followed up into recovery, and that multidimensional assessments are undertaken to unravel the influence of the various confounding factors on the observed endocrine changes in CFS.

This article has been cited by other articles:

				E. de Graaf-Roelfsema, P. P. Veldhuis, H. A. Keizer, M. M. E. van Ginneken, K. G. van Dam, M. L. Johnson, A. Barneveld, P. P. C. A. Menheere, E. van Breda, I. D. Wijnberg, et al. Overtrained horses alter their resting pulsatile growth hormone secretion Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2009; 297(2): R403 - R411. [Abstract] [Full Text] [PDF]

				C. Heim, U. M. Nater, E. Maloney, R. Boneva, J. F. Jones, and W. C. Reeves Childhood Trauma and Risk for Chronic Fatigue Syndrome: Association With Neuroendocrine Dysfunction Arch Gen Psychiatry, January 1, 2009; 66(1): 72 - 80. [Abstract] [Full Text] [PDF]

				U. M. Nater, L. S. Youngblood, J. F. Jones, E. R. Unger, A. H. Miller, W. C. Reeves, and C. Heim Alterations in Diurnal Salivary Cortisol Rhythm in a Population-Based Sample of Cases With Chronic Fatigue Syndrome Psychosom Med, April 1, 2008; 70(3): 298 - 305. [Abstract] [Full Text] [PDF]

				U. M. Nater, E. Maloney, R. S. Boneva, B. M. Gurbaxani, J.-M. Lin, J. F. Jones, W. C. Reeves, and C. Heim Attenuated Morning Salivary Cortisol Concentrations in a Population-Based Study of Persons with Chronic Fatigue Syndrome and Well Controls J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 703 - 709. [Abstract] [Full Text] [PDF]

				B. Van Houdenhove, L. Verheyen, K. Pardaens, P. Luyten, and P. Van Wambeke Rehabilitation of decreased motor performance in patients with chronic fatigue syndrome: should we treat low effort capacity or reduced effort tolerance? Clinical Rehabilitation, December 1, 2007; 21(12): 1121 - 1142. [Abstract] [PDF]

				E. Kajantie, K. Feldt, K. Raikkonen, D. I. W. Phillips, C. Osmond, K. Heinonen, A.-K. Pesonen, S. Andersson, D. J. P. Barker, and J. G. Eriksson Body Size at Birth Predicts Hypothalamic-Pituitary-Adrenal Axis Response to Psychosocial Stress at Age 60 to 70 Years J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4094 - 4100. [Abstract] [Full Text] [PDF]

				B. S. McEwen Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain Physiol Rev, July 1, 2007; 87(3): 873 - 904. [Abstract] [Full Text] [PDF]

				J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow Mechanisms of Cancer-Related Fatigue Oncologist, May 1, 2007; 12(suppl_1): 22 - 34. [Abstract] [Full Text] [PDF]

				C. Heim, D. Wagner, E. Maloney, D. A. Papanicolaou, L. Solomon, J. F. Jones, E. R. Unger, and W. C. Reeves Early Adverse Experience and Risk for Chronic Fatigue Syndrome: Results From a Population-Based Study. Arch Gen Psychiatry, November 1, 2006; 63(11): 1258 - 1266. [Abstract] [Full Text] [PDF]

				W. K. Jerjes, N. F. Taylor, T. J. Peters, S. Wessely, and A. J. Cleare Urinary Cortisol and Cortisol Metabolite Excretion in Chronic Fatigue Syndrome Psychosom Med, July 1, 2006; 68(4): 578 - 582. [Abstract] [Full Text] [PDF]

				A. Di Giorgio, M. Hudson, W. Jerjes, and A. J. Cleare 24-Hour Pituitary and Adrenal Hormone Profiles in Chronic Fatigue Syndrome Psychosom Med, May 1, 2005; 67(3): 433 - 440. [Abstract] [Full Text] [PDF]

				G. J. Rubin, M. Hotopf, A. Papadopoulos, and A. Cleare Salivary Cortisol as a Predictor of Postoperative Fatigue Psychosom Med, May 1, 2005; 67(3): 441 - 447. [Abstract] [Full Text] [PDF]

				A. Kier, J. Han, and L. Jacobson Chronic Treatment with the Monoamine Oxidase Inhibitor Phenelzine Increases Hypothalamic-Pituitary-Adrenocortical Activity in Male C57BL/6 Mice: Relevance to Atypical Depression Endocrinology, March 1, 2005; 146(3): 1338 - 1347. [Abstract] [Full Text] [PDF]

				S. J. Judge, C. D. Ingram, and S. E. Gartside Moderate differences in circulating corticosterone alter receptor-mediated regulation of 5-hydroxytryptamine neuronal activity J Psychopharmacol, December 1, 2004; 18(4): 475 - 483. [Abstract] [PDF]

				S. E. Straus Pharmacotherapy of Chronic Fatigue Syndrome: Another Gallant Attempt JAMA, September 8, 2004; 292(10): 1234 - 1235. [Full Text] [PDF]

				R. C. W. Vermeulen and H. R. Scholte Exploratory Open Label, Randomized Study of Acetyl- and Propionylcarnitine in Chronic Fatigue Syndrome Psychosom Med, March 1, 2004; 66(2): 276 - 282. [Abstract] [Full Text] [PDF]

				A. D. L. Roberts, S. Wessely, T. Chalder, A. Papadopoulos, and A. J. Cleare Salivary cortisol response to awakening in chronic fatigue syndrome The British Journal of Psychiatry, February 2, 2004; 184(2): 136 - 141. [Abstract] [Full Text] [PDF]